15 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss? https://www.zacks.com/stock/news/2261581/watch-these-3-medtech-stocks-this-earnings-season-beat-or-miss?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2261581 Apr 24, 2024 - Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
Why Labcorp (LH) Could Beat Earnings Estimates Again https://www.zacks.com/stock/news/2257935/why-labcorp-lh-could-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2257935 Apr 18, 2024 - Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? https://www.zacks.com/stock/news/2257691/labcorp-lh-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2257691 Apr 18, 2024 - Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) Extends MRD Clinical Research With New Launch https://www.zacks.com/stock/news/2252021/labcorp-lh-extends-mrd-clinical-research-with-new-launch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252021 Apr 08, 2024 - Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now https://www.zacks.com/stock/news/2249325/here-s-why-investors-should-retain-labcorp-lh-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2249325 Apr 02, 2024 - Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.
Labcorp (LH) to Boost Clinical Diagnostics With New Deal https://www.zacks.com/stock/news/2248657/labcorp-lh-to-boost-clinical-diagnostics-with-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2248657 Apr 01, 2024 - The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
Labcorp (LH) Presents New Research on Precision Diagnostics https://www.zacks.com/stock/news/2242254/labcorp-lh-presents-new-research-on-precision-diagnostics?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242254 Mar 18, 2024 - Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
Are Investors Undervaluing Labcorp (LH) Right Now? https://www.zacks.com/stock/news/2239239/are-investors-undervaluing-labcorp-lh-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2239239 Mar 12, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics (Revised) https://www.zacks.com/stock/news/2227695/compared-to-estimates-labcorp-lh-q4-earnings-a-look-at-key-metrics-revised?cid=CS-ZC-FT-fundamental_analysis|nfm-2227695 Feb 19, 2024 - Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp (LH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures https://www.zacks.com/stock/news/2224681/labcorp-lh-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2224681 Feb 12, 2024 - Get a deeper insight into the potential performance of Labcorp (LH) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Pages: 12

Page 1